bevacizumab + trastuzumab rezetecan

艾维达 + BP102 (trastuzumab rezetecan + bevacizumab) is an investigational combination therapy developed by Jiangsu Hengrui Pharmaceuticals for the treatment of HER2-expressing advanced solid tumors, particularly HER2-expressing metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC). Trastuzumab rezetecan (艾维达, SHR-A1811) is a novel HER2-targeted antibody-drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (trastuzumab) conjugated via a cleavable linker to a topoisomerase I inhibitor payload (rezetecan). BP102 (艾瑞妥) is a biosimilar of bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis. By combining the targeted cytotoxicity of the HER2 ADC with the anti-angiogenic effects of the VEGF-A inhibitor, this combination aims to synergistically inhibit tumor growth, disrupt tumor vasculature, and overcome resistance in HER2-expressing malignancies.